Orthocell Limited (ASX:OCC): FY26 Revenue and Remplir Nerve Repair Expansion

Aditi Sarkar

14 October 2026 12:25 AM AEDT

Orthocell Limited (ASX:OCC): FY26 Revenue and Remplir Nerve Repair Expansion

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Orthocell reported FY26 revenue of $13.2 million, a 44% increase.
June-quarter revenue reached $3.8 million, 20% above the March quarter.
Available funds at 30 June 2026 totalled $44.1 million.
US hospital access and surgical adoption of Remplir increased during the June quarter.
The company continued international regulatory and distribution activities for its collagen products.

Orthocell Limited (ASX:OCC) develops, manufactures and supplies regenerative medicine products for repairing nerve and other musculoskeletal tissue. Its collagen-based Remplir nerve repair device and Striate+ dental regeneration product form part of its commercial portfolio. During FY26, growth in product revenue coincided with an expanded United States distribution network and further international regulatory work.

FY26 Revenue and Cash Position

In its report for the quarter ended 30 June 2026, Orthocell Limited (ASX:OCC) disclosed full-year revenue of $13.2 million, up 44% from FY25. Revenue for the June quarter reached $3.8 million, compared with $3.2 million for the preceding March quarter. The June figure represented an increase of 36% against the corresponding quarter. These results reflected product adoption in existing territories and the expanding US commercial operation.

Available funds stood at $44.1 million on 30 June 2026. The company identified manufacturing expansion, product commercialisation and regulatory activity as uses for its financial resources. The funds figure is a reported period-end measure rather than a forecast of future cash availability, and expenditure on market development remains relevant to subsequent financial reporting.

Remplir Gains Access to More US Hospitals

US commercial activity centred on establishing surgeon access to Remplir. Orthocell Limited (ASX:OCC) said its distributor network covered approximately half of the US population at the end of the June quarter. Hospital Value Analysis Committee approvals increased to 44, providing access to 151 hospitals, while a further 64 applications were in progress. Such committees assess products before their use within individual hospitals.

The company reported 70 US hospitals purchasing Remplir and 76 surgeons using it. June-quarter unit sales were 119, and US revenue was $0.33 million. Approval to supply Remplir across US Department of Defense and Veterans Affairs healthcare networks expanded institutional access. Access and actual purchases are distinct commercial measures.

How the Collagen Platform Supports Nerve Repair

Remplir is a resorbable type I collagen device designed for use in peripheral nerve repair and related surgical procedures. Orthocell Limited (ASX:OCC) describes its collagen architecture as a scaffold that supports the healing environment around an injured nerve. The membrane is intended to protect the repair site; its use does not, by itself, establish a particular clinical outcome for every patient.

International Access and Clinical Work

Orthocell Limited (ASX:OCC) reported distributor appointments in Canada and Thailand in its June-quarter update. It also said regulatory approval had been obtained for Striate+ in Colombia and Ecuador. Remplir regulatory work continued for the United Kingdom and European Union, with the company indicating that approvals were anticipated by the end of calendar 2026. That timing was guidance, not a completed regulatory event.

In Australia, more than 250 nerve-sparing prostate surgery procedures using Remplir were reported across 39 surgeons. Orthocell also described ongoing clinical data collection and a US tendon-repair regulatory programme.

Commercial and Operational Considerations

For Orthocell Limited (ASX:OCC), the conversion of hospital access into repeat product orders is an important operational distinction. Other considerations include distributor execution, production capacity, clinical evidence, hospital procurement processes and regulatory decisions. Product availability across different markets does not mean the same indications or reimbursement arrangements apply in each jurisdiction.

Key Insights

Orthocell’s FY26 results show a growing revenue base alongside a wider US hospital and surgeon footprint for Remplir. The company’s reported $44.1 million in available funds provides a dated view of its resources as it undertakes manufacturing and market expansion. Its commercial progress, clinical work and outstanding regulatory applications are separate developments that require continued disclosure to assess.

FAQs

Q:What does Orthocell manufacture?

A:Orthocell develops regenerative medicine products, including the Remplir nerve repair device and Striate+ for dental regeneration.

Q:What was Orthocell’s FY26 revenue?

A:The company reported $13.2 million in revenue for FY26, representing a 44% increase.

Q:How much revenue did Orthocell report for the June 2026 quarter?

A:June-quarter revenue was $3.8 million.

Q:What progress did Remplir make in the United States?

A:At 30 June 2026, 70 hospitals were purchasing Remplir, and 76 surgeons had adopted the product.

Q:Were UK and EU Remplir approvals completed by June 2026?

A:No. The company described regulatory processes as ongoing and anticipated decisions by the end of calendar 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.